42 results about "Chimeric antibody" patented technology

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

Disclosed are a CD24 antibody or an antigen-binding fragment thereof and the medical use thereof. Further, disclosed are a chimeric antibody comprising CDRs of the CD24 antibody, a humanized antibody, a pharmaceutical composition comprising the CD24 antibody or the antigen-binding fragment thereof, and the use thereof as an anticancer drug.

The invention discloses an anti-human OX40 inhibitory antibody or an antigen binding fragment thereof, a preparation method and application, and belongs to the technical field of biological immunity. The EC50 of the human-mouse chimeric antibody Y07-L2 and the EC50 of the combination of the humanized antibody Y07-C2 and the human OX40, which are prepared by the invention, are close to those of a targeted antibody drug KHK-4083 for inhibiting the OX40. A heavy chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.14, and a light chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.15; the heavy chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.20, and the light chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.21; the CDR region of the humanized antibody Y07-C2 is mutated, and the mutant antibodies Y07-C2MH4 and Y07-C2MH4L3 are obviously superior to other antibodies.

The present invention provides anti-CD155 antibodies and their applications, and provides anti-CD155 chimeric antibodies, humanized antibodies, and affinity-matured humanized antibodies, which specifically target and bind to the CD155 receptor, inhibit the binding of CD155 to its receptors TIGIT, CD96, and CD226, and have the characteristic of not inducing apoptosis of CD155 cells.

The present invention provides anti-B7H3 antibodies and their application thereof A group of murine anti-B7H3 monoclonal antibodies are prepared by hybridoma technology, using recombinant B7H3 protein as immunogen. Human-murine chimeric antibodies generated from the aforementioned murine anti-B7H3 hybridomas are capable of specifically binding to recombinant B7H3 protein and membrane-bound B7H3 on tumor cell lines. The derived B7H3 scFv-CD3ε-engineered T cells exhibit a significant cytotoxic effect on B7H3-positive tumor cell lines. Therefore, the anti-B7H3 antibodies and B7H3 scFv-CD3ε-engineered T cells have great application prospects in treating or ameliorating B7H3-associated diseases.

Provided are an anti-BCMA antibody, an antigen-binding fragment thereof, and a medical use thereof. Further provided are a chimeric antibody and a humanized antibody containing a CDR region of the anti-BCMA antibody, a pharmaceutical composition containing the anti-BCMA antibody or the antigen-binding fragment thereof, and the use of same as an anti-cancer drug and for treating autoimmune diseases. Particularly, provided are a humanized anti-BCMA antibody, and the use of same in the preparation of a drug for treating BCMA-mediated diseases or conditions and the use of same in disease detection and diagnosis.

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a drug for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.

The present invention describes a chimeric antibody having specificity for FOLR1, a vector encoding the chimeric antibody, a recombinant host cell comprising the vector, and the use of the chimeric antibody in the preparation of bispecific antibodies and antibody drug conjugates.

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

The application relates to the field of biomedical technology, in particular to a monoclonal antibody specifically combined with EsxA and a therapeutic reagent; the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises three complementarity determining regions VLCDR1, VLCDR2 and VLCDR3, the heavy chain variable region comprises three complementarity determining regions VHCDR1, VHCDR2 and VHCDR3, the light chain variable region is an amino acid sequence identical to SEQ.ID.NO.1 at least 90%, 95%, 96%, 97%, 98%, 99% or 100%, and the heavy chain variable region is an amino acid sequence identical to SEQ.ID.NO.2 at least 90%, 95%, 96%, 97%, 98%, 99% or 100%; the therapeutic reagent comprises the monoclonal antibody, a single-chain antibody, a human-mouse chimeric antibody or a humanized antibody; the monoclonal antibody provided by the application is high in specificity, neutralization activity and protective power and is directed to EsxA, has the characteristics of mediating complement-dependent cytotoxicity, is excellent in in-vivo antibacterial activity and can support the construction of an anti-EsxA chimeric or humanized genetically engineered antibody with neutralization activity.

The present application belongs to the technical field of cellular immunization engineering, and particularly relates to a polypeptide specifically recognizing PSCA and application thereof. The polypeptide provided by the present application specifically recognizes PSCA and has good affinity performance. The polypeptide specifically targeting PSCA provided by the present application can mark PSCA positive cells, combine with PSCA antigen and PSCA positive cells, and can be used as a detection reagent for PSCA molecules and an in-vivo tracing labeling reagent. The polypeptide specifically targeting PSCA provided by the present application can also be used in an extracellular antigen recognition region of a chimeric antigen receptor, and can be used in an immune cell treatment drug targeting PSCA to kill malignant tumors expressing PSCA. The polypeptide specifically recognizing PSCA of the present application is derived from a natural full human antibody, and compared with a mouse-derived antibody, a chimeric antibody and a humanized antibody, the immunogenicity is greatly reduced, and the safety can be maximally ensured in clinical application.

This invention relates to the field of antibodies, and particularly to anti-EphA2 antibodies and their applications. This invention provides anti-EPH receptor A2 (EphA2) antibodies and their uses. This application also provides chimeric and humanized antibody forms of anti-EphA2 antibodies. These antibodies have high affinity for the human EphA2 protein and are promising antibody molecules for the prevention and / or treatment of EphA2-related diseases, such as EphA2-related tumors, osteoporosis, Alzheimer's disease, etc.

The present invention relates to monoclonal anti-human-(IDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

Disclosed in the present disclosure is genetically modified mice in which immunoglobulin loci are modified to insert gene segments of a human immunoglobulin variable region. The mice can be bred normally and produce human-mouse chimeric antibodies including a human variable region and a mouse constant region. The present disclosure also provides a method for preparing the genetically modified mice and use of the mice.

The present disclosure relates to anti-Claudin 18.2 antibodies and uses thereof. In particular, the present disclosure relates to an anti-Claudin 18.2 antibody; murine antibodies, chimeric antibodies, humanized antibodies and antigen-binding fragments thereof comprising the CDRs of the anti-Claudin 18.2 antibody, and uses thereof as a medicament. In particular, the present disclosure relates to the use of an anti-Claudin 18.2 antibody in the manufacture of a medicament for treating a Claudin 18.2 positive disease or disorder.

The present disclosure provides antigen binding regions and chimeric antibodies, as well as methods of making and using the same.

The present invention describes a chimeric antibody having specificity for FOLR1, a vector encoding the chimeric antibody, a recombinant host cell comprising the vector, and the use of the chimeric antibody in the preparation of bispecific antibodies and antibody drug conjugates.

Provided herein are, inter alia, antibodies (e.g., humanized antibodies, chimeric antibodies, monoclonal antibodies, biparatopic antibodies, antibody fragments (e.g., Fab')), which bind CD38 with high efficiency and specificity. Inter alia, are provided biparatopic antibodies that bind CD38 specifically and effectively. The biparatopic antibodies provided herein may have an increased binding avidity relative to the monoclonal antibodies they are derived from and are specifically useful for therapeutic and diagnostic purposes.

A human-mouse chimeric antibody against Dabie bunyavirus Np protein and application thereof, a light chain variable region of the antibody has a nucleotide sequence of SEQ ID NO:1 and an amino acid sequence of SEQ ID NO:2, wherein a light chain hypermutation region sequence has SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5; a heavy chain variable region has a nucleotide sequence of SEQ ID NO:6 and an amino acid sequence of SEQ ID NO:7, and a heavy chain hypermutation region has SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10. The antibody can specifically bind to Dabie bunyavirus antigen (Np). The immunochromatography reagent based on CDs / SiO2 fluorescent nanospheres has the advantages of simplicity, rapidness, high sensitivity, strong specificity and the like, and is suitable for on-site rapid detection.

Disclosed in the present disclosure is genetically modified mice in which immunoglobulin loci are modified to insert gene segments of a human immunoglobulin variable region. The mice can be bred normally and produce human-mouse chimeric antibodies including a human variable region and a mouse constant region. The present disclosure also provides a method for preparing the genetically modified mice and use of the mice.

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.

Compositions containing anti-LANCL1 antibodies, functional variants thereof, and methods of use thereof, are disclosed. An exemplary anti-LANCL1 antibody has a heavy chain variable region containing the CDRs, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, respectively, and a light chain variable region containing the CDRs, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24. Another exemplary anti-LANCL1 antibody has a heavy chain variable region containing the CDRs, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 respectively, and a light chain variable region containing the CDRs, SEQ ID NO:22, SEQ ID NO:73, SEQ ID NO:25, respectively. The antibody can be a monoclonal antibody, a human antibody, a chimeric antibody, or a humanized antibody. The disclosed compositions can be used to treat a subject in need thereof, for example a subject diagnosed with liver cancer or a subject at risk of developing liver cancer e.g., HCC.

The application discloses a pig-mouse chimeric antibody against porcine delta coronavirus and application thereof, wherein the pig-mouse chimeric antibody against porcine delta coronavirus is composed of a pig-derived heavy chain constant region, a pig-derived light chain constant region, a mouse-derived heavy chain variable region and a mouse-derived light chain variable region. The pig-mouse chimeric antibody can effectively reduce the heterogenic reaction of the antibody in a pig body, avoid the generation of an immune side reaction, shorten the half-life of the antibody, reduce actual curative effect and possibly cause serious adverse reactions, improve the neutralization treatment effect of the antibody, provide a practical genetically engineered antibody for prevention and treatment of PDCoV, and has important clinical application value.

This invention discloses a recombinant dimeric chimeric antibody against porcine epidemic diarrhea virus (PEDV), belonging to the field of antibody engineering technology. This invention creatively introduces the CH1 and hinge regions derived from IgG and the CH2-CH3 domains of IgA into the antibody structure to form a chimeric structure, improving the antibody's affinity and specificity, making it an ideal competitive reagent in blocking ELISA. The blocking ELISA kit developed based on this antibody has been clinically validated and can effectively distinguish between positive and negative samples, with a blocking rate of up to 79.7%, demonstrating promising application prospects.

There is provided a compound of formula (I) wherein the conjugate is a group capable of binding a BA and joining the BA to the remainder of the compound, the cleavable quantum comprises at least one site capable of being cleaved by a beta-glucuronidase, the spacer provides a distance between the conjugate and a payload, the payload being a cytotoxic agent, such as MMAE, and BA is a binding agent selected from the group consisting of a humanized antibody, a monoclonal antibody, a chimeric antibody or a human antibody or an antigen-binding fragment thereof. (I)

The application discloses an inhibitory antibody or antigen-binding fragment thereof against human OX40, a preparation method and application, and belongs to the technical field of biological immunity. The human-mouse chimeric antibody Y07-L2 and the humanized antibody Y07-C2 prepared by the application have similar EC50 in combination with human OX40, and are similar to the targeted antibody drug KHK-4083 in inhibiting OX40. The heavy chain variable region of the human-mouse chimeric antibody Y07-L2 is shown as SEQ ID NO. 14, and the light chain variable region is shown as SEQ ID NO. 15; the heavy chain variable region of the humanized antibody Y07-C2 is shown as SEQ ID NO. 20, and the light chain variable region of the humanized antibody Y07-C2 is shown as SEQ ID NO. 21; the CDR region of the humanized antibody Y07-C2 is subjected to mutation, and the mutant antibody Y07-C2MH4 and Y07-C2MH4L3 are obviously superior to other antibodies.

Disclosed herein are systems, compositions and methods for combined tumor therapy using CAR-T cells and administered bubbles accompanied by application of low frequency ultrasound (US).

The application belongs to the field of antibodies, and particularly relates to anti-IL-23 antibodies and genetically engineered products and applications thereof. The anti-IL-23 antibody is a human-mouse chimeric antibody, the amino acid sequence of the heavy chain CDR region is shown as SEQ ID NO. 1-SEQ ID NO. 3, the amino acid sequence of the light chain CDR region is shown as SEQ ID NO. 4-SEQ ID NO. 6, the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 7, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 8. The anti-IL-23 antibody provided in the application has high affinity, strong specificity, is directed against the p19 subunit, and has excellent blocking effect. The application provides technical support for the prevention, adjuvant treatment or treatment of autoimmune and chronic inflammatory diseases.

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.